Key result
A 6-minute walk distance ≥400 m was associated with a lower rate of cardiopulmonary complications in patients undergoing lobectomy for lung cancer (OR 0.53; 95% CI 0.35-0.81).
Why the study?
The 6-min walk test is not included in guidelines for functional evaluation before lung cancer resection due to inconsistent data regarding its clinical value.
Does a 6-minute walk distance ≥400 m or DSP ≥350 m% predict a lower risk of cardiopulmonary complications in patients undergoing lobectomy for lung cancer?
Population
947 patients undergoing a single lobectomy for lung cancer
Comparison
6MWD and DSP test performance vs shorter distance or lower DSP values
Design
Retrospective study
Authors
Loading...
May aid risk stratification in lobectomy candidates with reduced predicted lung function; leaves open whether 6MWT thresholds improve outcomes prospectively.
Cohort (n=947)
Does a 6-minute walk distance ≥400 m or DSP ≥350 m% predict a lower risk of cardiopulmonary complications in patients undergoing lobectomy for lung cancer?
Odds Ratio: 0.53 (95% CI 0.35–0.81)
The 6-minute walk test is a useful low-technology tool to stratify the risk of postoperative cardiopulmonary complications in lung cancer patients undergoing lobectomy.
Wesółowski et al. (2019) conducted a cohort in lung cancer (n=947). 6-minute walk distance (6MWD) ≥400 m vs. shorter 6MWD was evaluated on cardiopulmonary complications (OR 0.53, 95% CI 0.35-0.81). A 6-minute walk distance ≥400 m was associated with a lower rate of cardiopulmonary complications in patients undergoing lobectomy for lung cancer (OR 0.53; 95% CI 0.35-0.81).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: